Sugi Predict

Sugi Predict / Targets / ZKSCAN2

ZKSCAN2

Zinc finger protein with KRAB and SCAN domains 2 · Q63HK3 · ZKSCAN2 on Sugi Atlas →

0 patent compounds predicted against ZKSCAN2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ZKSCAN2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer PHASE1/PHASE2SUSPENDED
Safety and Dose Escalation Study of Zinc Supplementation in Critically Ill Children PHASE1/PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) EARLY_PHASE1UNKNOWN
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma nanUNKNOWN
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy nanUNKNOWN
EKLF Gene Expression in β-thalassemia nanNOT_YET_RECRUITING
Map of Tumor Genetic Actionability in Argentina nanACTIVE_NOT_RECRUITING
Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients nanNOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Immune Cell Response to Stimuli nanRECRUITING
COPENHAGEN Minipuberty Study nanUNKNOWN
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B) nanCOMPLETED
Risk of HCC in Cirrhotic Patients Post DAAs Ttt nanUNKNOWN
Familial Investigations of Childhood Cancer Predisposition nanRECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a ZKSCAN2 binder may also engage these)

ProteinNameSimilarity
Q8BGS3 — 0.999 Q8BGS3 →
Q8IWY8 — 0.999 Q8IWY8 →
Q4R8H9 — 0.999 Q4R8H9 →
A2T7D2 — 0.998 A2T7D2 →
Q53GI3 — 0.995 Q53GI3 →
P59923 — 0.995 P59923 →
Q96GC6 — 0.994 Q96GC6 →
Q8BGV5 — 0.994 Q8BGV5 →
Q5R741 — 0.994 Q5R741 →
P17029 — 0.994 P17029 →
Q4V8E9 — 0.994 Q4V8E9 →
Q5R670 — 0.994 Q5R670 →
Q921B4 — 0.994 Q921B4 →
A2T6W2 — 0.993 A2T6W2 →
A1YG26 — 0.993 A1YG26 →
Q9NX65 — 0.993 Q9NX65 →
A2T736 — 0.993 A2T736 →
B2KFW1 — 0.993 B2KFW1 →
A1YFW6 — 0.993 A1YFW6 →
Q4KLI1 — 0.993 Q4KLI1 →
A1YFW2 — 0.992 A1YFW2 →
A6QPT6 — 0.992 A6QPT6 →
Q969J2 — 0.992 Q969J2 →
Q9Z1D7 — 0.992 Q9Z1D7 →
Q9Z2K3 — 0.992 Q9Z2K3 →
Q15776 — 0.992 Q15776 →
Q923B3 — 0.992 Q923B3 →
Q9Z1D9 — 0.992 Q9Z1D9 →
P10073 — 0.992 P10073 →
Q9UJL9 — 0.992 Q9UJL9 →